The anti-epileptic drug Valproic Acid (VPA) inhibits steroidogenesis in bovine theca and granulosa cells in vitro by Glister, Claire et al.
The Anti-Epileptic Drug Valproic Acid (VPA) Inhibits
Steroidogenesis in Bovine Theca and Granulosa Cells
In Vitro
Claire Glister1, Leanne Satchell1, Anthony E. Michael2, Andrew B. Bicknell1, Philip G. Knight1*
1 School of Biological Sciences, University of Reading, Reading, Berkshire, United Kingdom, 2Division of Biomedical Sciences, St George’s University of London, London,
United Kingdom
Abstract
Valproic acid (VPA) is used widely to treat epilepsy and bipolar disorder. Women undergoing VPA treatment reportedly have
an increased incidence of polycystic ovarian syndrome (PCOS)-like symptoms including hyperandrogenism and oligo- or
amenorrhoea. To investigate potential direct effects of VPA on ovarian steroidogenesis we used primary bovine theca (TC)
and granulosa (GC) cells maintained under conditions that preserve their ‘follicular’ phenotype. Effects of VPA (7.8–500 mg/
ml) on TC were tested with/without LH. Effects of VPA on GC were tested with/without FSH or IGF analogue. VPA reduced
(P,0.0001) both basal (70% suppression; IC50 67610 mg/ml) and LH-induced (93% suppression; IC50 58610 mg/ml)
androstenedione secretion by TC. VPA reduced CYP17A1 mRNA abundance (.99% decrease; P,0.0001) with lesser effects
on LHR, STAR, CYP11A1 and HSD3B1 mRNA (,90% decrease; P,0.05). VPA only reduced TC progesterone secretion induced
by the highest (luteinizing) LH dose tested; TC number was unaffected by VPA. At higher concentrations (125–500 mg/ml)
VPA inhibited basal, FSH- and IGF-stimulated estradiol secretion (P,0.0001) by GC without affecting progesterone secretion
or cell number. VPA reversed FSH-induced upregulation of CYP19A1 and HSD17B1 mRNA abundance (P,0.001). The potent
histone deacetylase (HDAC) inhibitors trichostatin A and scriptaid also suppressed TC androstenedione secretion and
granulosal cell oestrogen secretion suggesting that the action of VPA reflects its HDAC inhibitory properties. In conclusion,
these findings refute the hypothesis that VPA has a direct stimulatory action on TC androgen output. On the contrary, VPA
inhibits both LH-dependent androgen production and FSH/IGF-dependent estradiol production in this in vitro bovine
model, likely by inhibition of HDAC.
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Introduction
Epilepsy is a common disorder affecting over 1% of the
population, including almost one million women of child bearing
age [1]. Therapeutic drugs successfully control seizures in about
70% of patients. However, medication is long-term and side effects
are common; these include effects on the reproductive endocrine
system of both males and females (reviews: [2,3,4]). One of the
most widely prescribed anti-epileptic drugs is valproic acid (VPA),
a branched-chain fatty acid with anti-convulsant and mood
stabilizing properties (review [5]). VPA is also used in the
treatment of bipolar disorders, migraines and neuropathic pain.
The anti-convulsant and mood stabilizing properties of VPA have
been attributed to modulation of voltage-dependent sodium
channels, enhancement of GABA inhibitory neurotransmission
and/or decreased cerebral glucose metabolism [5].VPA is also
known to affect various intracellular signal transduction pathways
including MAPK, PKB and PKC-mediated pathways [6,7] as well
as being an inhibitor of type 1 histone deacetylase (HDAC) [8].
Over the past 15 years it has emerged that there is an increased
incidence of polycystic ovarian syndrome (PCOS)-like symptoms
in epileptic women taking VPA suggesting that the drug can
perturb ovarian function and androgen synthesis, possibly as a
result of multiple effects on the hypothalamic-pituitary-ovarian
axis (reviews: [2,3,5,9]). PCOS is a very common reproductive
endocrine disorder affecting 6–8% of women of reproductive age
[10,11]; despite intensive research, its aetiology remains largely
unknown. PCOS is usually defined by the presence of hyperan-
drogenism (in the absence of specific adrenal and/or pituitary
disease), oligo- or amenorrhoea and characteristic ‘polycystic’
ovarian morphology as revealed by ultrasonography [11,12].
However, PCOS is also strongly associated with obesity, insulin
resistance and hyperinsulinemia, features of the so-called ‘meta-
bolic syndrome’ [10,12].
The association between VPA treatment and PCOS-like
symptoms was first reported by Isojarvi et al. [13] who found that
almost 50% of women treated for epilepsy with VPA had
amenorrhea, oligomenorrhoea or prolonged menstrual cycles
compared with 19% of women taking carbamazepine, another
anti-epileptic drug. In a later study Isojarvi et al. [14] reported that
64% of women receiving VPA had polycystic ovaries and/or
hyperandrogenism. In addition to raised serum androgen levels
these women were obese, had high fasting serum insulin levels and
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low levels of serum insulin-like growth factor-binding protein 1.
O’Donovan et al. [15] reported that 41% of women taking VPA
medication for bipolar disorder exhibited PCOS; more women
reported menstrual abnormalities in the VPA group (47%) than in
the group not receiving VPA (13%). Other studies [16,17] have
documented higher plasma testosterone and free-androgen levels
in women treated with VPA.
Several mechanistic studies, both in vivo and in vitro, have
investigated the link between VPA exposure, PCOS-like symptoms
and ovarian hyperandrogenism (review: [4]). Most of these have
relied on animal models. For instance, Tauboll et al. [18] reported
that chronic VPA treatment in rats increased the number of
follicular ‘cysts’ and raised total ovarian weight but decreased
plasma testosterone concentrations. In contrast, Sveberg Roste
et al. [19] found that chronic VPA exposure in female rats did not
affect serum androgen levels but dramatically reduced serum
estrogen levels, thus raising the androgen: estrogen ratio. Ferin
et al. [20] reported that long-term VPA treatment in normally
cycling rhesus monkeys had no effect on androgen levels or
ovarian morphology. In an in vitro study using propagated human
ovarian thecal cells (TC) it was shown that VPA treatment
augmented ovarian androgen synthesis and increased transcription
of steroidogenic genes [21]. However, Fisseha et al. [22] reported
an inhibitory effect of VPA on hCG-induced androgen secretion
by rat theca-interstitial cells. Using a porcine TC-GC co-culture
model, Tauboll et al. [23] found that VPA increased basal and LH-
stimulated androgen secretion by cells from small follicles but
decreased LH-stimulated androgen secretion by cells from
medium-size follicles. In addition, they showed that VPA reduced
basal and FSH-induced estradiol secretion.
Given these inconsistencies in the literature regarding the effects
of VPA on the female reproductive endocrine axis, the aim of the
present study was to re-evaluate the potential direct ovarian effects
of VPA using well-established bovine TC and GC culture models
in which the cells retain a non-luteinized ‘follicular’ phenotype and
are highly responsive to LH and FSH, respectively. The cow, like
the human, is a mono-ovulatory species and human ovaries share
many more similarities with bovine ovaries than they do with
rodent or porcine ovaries. As such the bovine ovary is regarded as
an excellent model for the human ovary [24,25].
Results
Effect of VPA on Basal and LH-induced Androstenedione
and Progesterone Secretion by TC
Consistent with our previous observations using this in vitro TC
model [26] treatment of cells with an optimal dose-level of LH
(100 pg/ml) promoted a robust increase in androstenedione
secretion (,6-fold; P,0.0001) but did not affect progesterone
secretion (Fig. 1). At a much higher ‘luteinizing’ dose-level
(2500 pg/ml) LH promoted a marked increase in secretion of
progesterone but not androstenedione. A small though significant
(P,0.0001) decrease in cell number was also elicited by LH. VPA
had a marked and dose-dependent suppressive effect on basal
androstenedione secretion (IC50 67610 mg/ml; P,0.0001) and
androstenedione secretion induced by the optimal dose-level of
LH (IC50 58610 mg/ml; P,0.0001). VPA also had a modest
suppressive effect on progesterone secretion (IC50.250 mg/ml)
induced by the highest LH dose-level. VPA had no effect on viable
cell number at the end of culture (Fig. 1).
Effect of VPA and Basal and LH-induced Gene Expression
in TC
The effects of VPA (250 mg/ml) and LH (100 pg/ml) on the
relative abundance of six key mRNA transcripts involved in TC
steroidogenesis are shown in Fig. 2. LH increased the abundance
of STAR mRNA (5-fold; P,0.01) and tended to increase CYP17A1
mRNA (3-fold, P.0.05) but did not significantly affect LHR,
CYP11A1, HSD3B1 or HSD17B1 mRNA abundance. VPA had a
profound suppressive effect on CYP17A1 transcript abundance,
both in the presence and absence of LH stimulation (.99%
reduction; P,0.0001). VPA also reduced expression of LHR,
STAR, CYP11A1 and HSD3B1 under basal and LH-stimulated
conditions (,50% to 90% reduction; P,0.05) but to a much lesser
extent than the suppression of CYP17A1 mRNA.
Effect of VPA on Basal, FSH- and IGF-induced Estradiol
and Progesterone Secretion by GC
VPA dose-dependently suppressed basal (IC50 ,250 mg/ml;
P,0.01) and FSH-induced (IC50 ,200 mg/ml; P,0.0001) secre-
tion of estradiol but did not influence progesterone secretion or
viable cell number at the end of culture (Fig. 3). Similarly, VPA
dose-dependently reversed the stimulatory effect of IGF analogue
on estradiol secretion (IC50 ,250 mg/ml; P,0.001) without
affecting progesterone secretion or cell number (Fig. 4).
Effect of VPA on Basal, FSH-induced and IGF-induced
Gene Expression in GC
As anticipated FSH greatly increased the relative abundance of
CYP19A1 (76-fold; P,0.0001) and HSD17B1 (7-fold; P,0.01)
mRNA in GC, paralleling the FSH-induced increase in estradiol
secretion by the cells (Fig. 5). Concomitantly, FSH slightly reduced
the abundance of STAR and HSD3B1 mRNA, consistent with the
small reduction in progesterone secretion observed. VPA reversed
the FSH-induced upregulation of CYP19A1 and HSD17B1 expres-
sion (P,0.001). Likewise the FSH-induced reduction in STAR and
HSD3B1 expressionwas reversedbyVPAtreatment.NeitherFSHor
VPA, alone or in combination, had any significant effect on
abundance of FSHR or IGF1R transcripts.
As shown in Fig. 6 treatment of GC with IGF analogue also
upregulated the abundance of CYP19A1 (71-fold; P,0.0001) and
HSD17B1 (8-fold; P,0.01) transcripts consistent with the
observed IGF-induced increase in estradiol secretion. Co-treat-
ment with VPA partially reversed these increases in CYP19A1 and
HSD17B1 mRNA. Neither IGF analogue or VPA, alone or in
combination, had any significant effect on abundance of FSHR or
IGF1R transcripts in GC.
Comparison of the Effect of Three Different HDAC
Inhibitors on TC Androgen Secretion and GC Estrogen
Secretion
To explore the possibility that the suppressive action of VPA on
TC androgen secretion and GC estrogen secretion reflects its
HDAC inhibitory properties, we conducted a further experiment
to compare the effects of VPA (250 mg/ml; ,2 mM) with those of
two highly potent HDAC inhibitors, scriptaid and trichostatin A at
5 nM and 500 nM, respectively. As shown in Fig. 7 all three
compounds inhibited basal and LH-induced secretion of andro-
stenedione by TC and FSH-induced secretion of estrogen by GC.
Discussion
In view of considerable evidence that women undergoing VPA
treatment for epilepsy and bipolar disorder show an increased
VPA Suppresses Ovarian Steroidogenesis In Vitro
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incidence of PCOS-like symptoms including hyperandrogenemia
and menstrual cycle disturbances (reviewed by: [2,3,5]), research is
clearlywarrantedtotry toclarify themechanism(s) throughwhichthis
widelyprescribeddrugmightelicit suchaneffectonovarian function.
Potentially VPA could perturb ovarian function by acting at one or
more levels of the hypothalamic-pituitary-ovarian axis, or by
modifying some other organ that influences ovarian function
indirectly (e.g. pancreatic insulin secretion). This study, together
with several previous studies discussed below, sought evidence for a
direct action of VPA on ovarian steroidogenesis. Importantly, the
present in vitro data presented firmly refute the hypothesis that VPA
has a direct stimulatory effect on thecal androgen production.
Using well defined in vitro model systems based on primary
cultures of bovine TC [26,27,28,29] and GC [30,31,32,33] the
present study shows that VPA has a direct, dose-dependent
inhibitory action on ovarian steroidogenesis, suppressing both
basal and LH-induced androgen production by TC as well as
FSH- and IGF-induced estrogen production by GC. With regard
to TC, our findings concur with those of a recent study [22]
documenting a VPA-induced inhibition of basal and hCG-induced
androgen secretion by rat theca-interstitial cells. Moreover,
chronic VPA treatment in vivo was shown to decrease plasma
testosterone concentrations in rats [18]. However, these findings
contradict those of a study on propagated (4th passage) human TC
[21] showing that VPA stimulated basal and forskolin-induced
androgen secretion, and raised cellular levels of CYP17A1
(cytochrome P450c17) and CYP11A1 (cytochrome P450scc)
protein. In another in vitro study utilizing a porcine TC/GC co-
culture model [23] VPA was found to stimulate androgen
secretion by small follicles but to inhibit androgen secretion by
medium-size follicles. The reasons for these inconsistencies
amongst in vitro studies in different laboratories are currently
Figure 1. Effects of VPA on basal and LH-induced secretion of (A) androstenedione and (B) progesterone by bovine theca-interna
cells; panel (C) shows viable cell number at the end of culture. Values are means 6 SEM (n = 4 independent experiments). Results of 2-way
ANOVA are indicated.
doi:10.1371/journal.pone.0049553.g001
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unknown but species differences are likely a major contributory
factor, along with methodological differences with regard to
culture conditions (cell harvesting, plating density, culture media,
use of serum supplementation, culture duration, extent to which
cells have been propagated) that may affect the behaviour and/or
phenotype of cells in vitro. In the case of the porcine TC/GC co-
culture model, another factor complicating the interpretation of
these data is the ability of porcine TC to synthesize considerable
amounts of estrogen [34]. Bovine TC, like those of human, mouse,
rat and sheep, do not express CYP19A1 and are incapable of
estrogen synthesis.
The short term primary cultures of bovine TC and GC used in
the present study are believed to provide a physiologically relevant
model in the sense that the cells retain a non-luteinized (‘follicular’)
phenotype over the 6-day culture period under chemically defined,
serum-free conditions. These cells are highly responsive to
gonadotrophin stimulation in terms of LH-induced androgen
secretion by TC, FSH- and IGF-induced estradiol, inhibin and
activin secretion by GC and expression of genes involved in
steroidogenesis including LHR and CYP17A1 in TC and FSHR and
CYP19A1 in GC [26,27,28,29,31,32,33,35,36].
Examination of steady-state mRNA levels in control and VPA-
treated TC revealed a clear-cut inhibition by VPA of five key
Figure 2. Effects of VPA in the presence and absence of LH on the relative abundance of six key steroidogenic transcripts in bovine
theca-interna cells. Values are means 6 SEM (n = 7 independent experiments). Means without a common letter are significantly different (P,0.05).
doi:10.1371/journal.pone.0049553.g002
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genes involved in the steroidogenic response, most notably
CYP17A1 (.99% suppression) with a much lesser degree of
inhibition of LHR, STAR, CYP11A1 and HSD3B1 transcript
abundance. Likewise, Fisseha et al. [22] showed that VPA reduced
CYP17A1 expression by rat theca-interstitial cells cultured under
both basal and hCG-stimulated conditions, although effects on
LHR, STAR, CYP11A1 and HSD3B1 expression were not reported.
These authors also showed a comparable inhibitory effect of VPA
on the androgen response to 8-bromo-cyclic adenosine-3959-
monophosphate (8-Br-cAMP), indicating that VPA exerts its
suppressive action at a level distal to cAMP generation following
LH/CG receptor activation.
The profound suppression of both basal and LH-induced
androgen secretion we observed can best be accounted for by the
severe reduction in CYP17A1 expression since progesterone
secretion was not suppressed by VPA, except in the presence of
a very high dose-level of LH that, as anticipated, promoted cell
luteinisation as evidenced by a marked increase in progesterone
secretion and a loss of androgen secretion [26,37]. Indeed, VPA
tended to increase progesterone secretion in cells incubated
without LH or with a very low concentration of LH (4 pg/ml),
indicating that steps in the steroidogenic pathway proximal to
CYP17A1 catalysis were not rate-limiting under these conditions.
The lack of effect of VPA on viable cell number recorded at the
end of culture indicates that VPA does not affect cell proliferation
and/or survival during the 4-day treatment period.
With regard to GC, our finding that VPA also suppressed basal,
FSH-induced and IGF-induced secretion of estradiol-17b by
cultured GC is consistent with several in vitro and in vivo studies.
Using GC harvested from women undergoing laparotomy proce-
dures for infertility treatmentTauboll et al. [38]recentlyreportedthat
VPA suppressed basal and FSH-induced estradiol secretion.
Figure 3. Effects of VPA on basal and FSH-induced secretion of (A) estradiol and (B) progesterone by bovine granulosa cells; panel
(C) shows viable cell number at the end of culture. Values are means 6 SEM (n= 4 independent experiments). Results of 2-way ANOVA are
indicated.
doi:10.1371/journal.pone.0049553.g003
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Similarly, in the porcine TC/GC co-culture study of Tauboll et al.
[23] VPA reduced basal and FSH-induced estrogen secretion.
Chronic in vivo exposure of rats to VPA greatly reduced circulating
estrogen levels, although androgen levels were not affected [19].
However, long-term in vivo treatment of rhesus monkeys with VPA
had no effect on circulating estradiol or androgen levels and did not
affect menstrual cyclicity or ovarian morphology [20].
QPCR analysis of GC levels of six key transcripts involved in
steroidogenesis revealed that VPA did not affect the abundance of
FSHR or IGF1R mRNA suggesting that the inhibitory action of
VPA on estrogen secretion did not involve downregulation of
either receptor. However, VPA completely reversed FSH-induced
expression of CYP19A1 and HSD17B1 and partially reversed IGF-
induced CYP19A1 and HSD17B1 expression. An inhibitory effect
of VPA on CYP19A1 in FSH-treated human GC was also observed
by Tauboll et al. [38]. As discussed below the enzymes encoded by
CYP19A1 and HSD17B1 both play key roles in the synthesis of
estradiol-17b by GC.
VPA was some 4-fold more potent in suppressing TC
androgen production (IC50 ,60 mg/ml) than GC estradiol
production (IC50 ,250 mg/ml), the former value being within
the therapeutic serum range for human subjects of about 50–
100 mg/ml [39]. Since TC-derived androgens are an obligatory
substrate for GC the CYP19A1 (cytochrome P450 aromatase)
Figure 4. Effects of VPA on basal and LR3-IGF-1 (IGF)-induced secretion of (A) estradiol and (B) progesterone by bovine granulosa
cells; panel (C) shows viable cell number at the end of culture. Values are means 6 SEM (n = 4 independent experiments). Results of 2-way
ANOVA are indicated.
doi:10.1371/journal.pone.0049553.g004
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enzyme, and hence follicular estrogen synthesis [40,41], in an
in vivo context this implies a dual inhibitory action of VPA on
follicular estrogen production primarily by depriving GC of
aromatase substrate and secondarily by inhibiting FSH- and
IGF-induced upregulation of CYP19A1 and HSD17B1 expression
by GC. Androstenedione is the principle androgen produced by
bovine (and human) TC, and the17b-hydroxysteroid dehydro-
genase enzyme (HSD17B1) is required to convert the product of
its aromatization, estrone, into estradiol-17b, the principle
ovarian estrogen [40,41]. Despite the above, on the basis of
the relative IC50 values, it is more likely that the predominant
direct ovarian effect of VPA at therapeutically relevant
concentrations is exerted on TC rather than GC.
The extent to which observations made using different animal
models, including the present bovine ovarian cell culture systems,
can be extrapolated to human ovarian function is uncertain.
However, in contrast to rodent and porcine ovaries used for many
of the previous VPA-associated studies, there are striking
similarities between human and bovine ovaries in terms of
morphology, follicle size-range, developmental time-line, steroido-
genic activity, ovulation rate and physiological regulation by
endocrine and intraovarian factors [24,25,42,43]. Given these
similarities, and considering the practical and ethical constraints
associated with accessing human ovarian tissue for in vitro studies,
the likelihood is that insights gained from pharmacological studies
using bovine in vitro models are indeed relevant to translational
and biomedical research on human ovarian function.
With regard to the mechanism through which VPA
suppresses androgen secretion by theca cells, our observation
that two highly potent HDAC inhibitors, scriptaid (pan-HDAC
inhibitor) and trichostatin A (type 1and 2 HDAC inhibitor) also
suppressed androstenedione secretion, supports the notion that
the action of VPA is due to its activity as a type 1 HDAC
inhibitor [8,44,45]. Since TC expression of LH receptor and
each of the steroidogenic proteins suppressed by VPA (STAR,
CYP11A1, CYP17A1 and HSD3B1) is known to be partially
dependent on the common transcription factor, steroidogenic
factor-1 (SF-1; NR5A1) [46], we speculate that repressed
Figure 5. Effects of VPA in the presence and absence of FSH on the relative abundance of six key steroidogenic transcripts in
bovine granulosa cells. Values are means 6 SEM (n= 4 independent experiments). Means without a common letter are significantly different
(P,0.05).
doi:10.1371/journal.pone.0049553.g005
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transcription and/or posttranslational modification of SF-1
could provide a plausible explanation for the inhibition of
androgen synthesis observed under both basal and LH-
stimulated conditions. In support of this, a previous study using
steroidogenic adrenocortical cell lines found that VPA (and
other HDAC inhibitors) targets SF-1 for ubiquitination and
degradation [47]. Clearly, further mechanistic studies are
required to delineate the cellular and molecular pathways
through which VPA and other HDAC inhibitors modulate
ovarian steroidogenesis at the level of both theca and granulosa
cells. The observation that all three HDAC inhibitors also
inhibited FSH-induced estradiol secretion by GC suggests a
similar mechanism of action on this cell type.
In conclusion, the present findings do not support the
hypothesis that VPA has a direct action on the ovary to raise
thecal androgen production. Conversely, our evidence firmly
indicates a VPA-induced inhibition of both TC androgen
production and GC estrogen production arising primarily from
a suppression of CYP17A1 and CYP19A1 mRNA levels in the
respective cell-types. Irrespective of the mechanism of action of
VPA, our findings underscore the need for further in vivo
studies, particularly clinical studies in humans, to re-evaluate
whether this widely prescribed drug does indeed promote
hyperandrogenism through a direct stimulatory action on
ovarian theca cells.
Materials and Methods
Bovine Ovaries and Cell Culture
Bovine GC and TC were isolated from adult bovine ovaries
obtained from a local abattoir (St Merryn Meat Ltd) as described
in detail elsewhere [26,27,32]. For each experiment cells pooled
Figure 6. Effects of VPA in the presence and absence of LR3-IGF on the relative abundance of six key steroidogenic transcripts in
bovine granulosa cells. Values are means 6 SEM (n= 4 independent experiments). Means without a common letter are significantly different
(P,0.05).
doi:10.1371/journal.pone.0049553.g006
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Figure 7. Three different HDAC inhibitors (trichostatin A; 5 nM), scriptaid; 500 nM) and VPA; 2 mM) have similar inhibitory effects
on (A) basal and LH-induced androstenedione secretion by bovine theca cells and (B) basal and FSH-induced estrogen secretion by
bovine granulosa cells. Values are means 6 SEM (n= 4 independent cultures). *p,0.05, ***p,0.001 compared to corresponding group without
inhibitor.
doi:10.1371/journal.pone.0049553.g007
Table 1. List of primers used for real-time PCR.
Target
Accession
number
Forward primer
5’ to 3’
Reverse primer
5’ to 3’
Amplicon
size (bp)
FSHR NM_174061.1 GCCAGCCTCACCTACCCCAGC AATTGGATGAAGGTCAGAGGTTTGCC 75
LHR NM_174381.1 ATTGCCTCAGTCGATGCCCAGACC AAAAAGCCAGCCGCGCTGC 92
IGF1R XM_606794.3 ACCTCCCAGCCTAAGCAAAATGATCC TCTTCGGCCACCATGCAGTTCC 123
STAR NM_174189 TTTTTTCCTGGGTCCTGACAGCGTC ACAACCTGATCCTTGGGTTCTGCACC 103
CYP11A1 NM_176644 CAGTGTCCCTCTGCTCAACGTCC TTATTGAAAATTGTGTCCCATGCGG 99
HSD3B1 NM_174343.2 GCCACCTAGTGACTCTTTCCAACAGCG TGGTTTTCTGCTTGGCTTCCTCCC 111
CYP17A1 NM_174304 GACAAAGGCACAGACGTTGTGGTCA TGATCTGCAAGACGAGACTGGCATG 301
CYP19A1 NM_174305.1 CGCCACTGAGTTGATTTTTGCTGAGA TAAGGCTTTGCGCATGACCAGGTC 301
HSD17B1 NM_001102365 CGCATATTGGTGACCGGGAGCATA AATCGCCAGACTCTCGCACAAACC 108
ACTB NM_173979.3 ATCACCATCGGCAATGAGCGGTTC CGGATGTCGACGTCACACTTCATGA 128
doi:10.1371/journal.pone.0049553.t001
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from approximately 50 individual 4–6 mm follicles were routinely
plated out in 96-well tissue culture plates (Nunclon, Life
Technologies Ltd, Paisley, UK) at 75,000 viable cells/well
(estimated using trypan blue) and cultured for 6 days under
defined serum-free conditions. The culture medium used for both
cell-types consisted of McCoy’s 5A modified medium supplement-
ed with 1% (v/v) antibiotic-antimycotic solution, 10 ng/ml bovine
insulin, 2 mM L-glutamine, 10 mM HEPES, 5 mg/ml apo-
transferrin, 5 ng/ml sodium selenite and 0.1% (w/v) BSA (all
purchased from Sigma). In the case of GC the culture medium was
supplemented with androstenedione (Sigma UK Ltd, Poole,
Dorset, UK) at 1027 mol/l as a substrate for CYP19A1
(cytochrome P450 aromatase). Medium was removed after 48 h
and 96 h and replaced with fresh media containing treatments as
indicated below. Conditioned media were retained for assay and at
the end of the culture period viable cell number was determined
by neutral red dye uptake assay to provide an assessment of cell
proliferation/survival.
In culture experiments in which total RNA was to be extracted
for PCR analysis, cells were seeded into 24-well plates (105 cells/
ml) with 3 replicate wells per treatment. At the end of culture cell
lysates were prepared using Tri-Reagent (Sigma) and pooled
lysates from replicate wells were stored at 280C until total RNA
isolation.
Treatments
Ovine LH (NIADDK oLH-S-16) and FSH (NIADDK oFSH-
19SIAPP) were obtained from NHPP, Torrance, CA, USA.
Recombinant IGF-1 analogue (Long R3 IGF-1) and VPA, were
purchased from Sigma. Treatments were dissolved in Hank’s
balanced salt solution containing 0.1% (w/v) BSA and stock
solutions sterilized using 0.2 mm membrane filters before dilution
in sterile culture medium. Scriptaid (Sigma) and trichostatin A
(Sigma) were dissolved in DMSO (10 mM) before further dilution
in sterile culture medium.
Steroid Assays
Concentrations of androstenedione in TC-conditioned media
were determined by radioimmunoassay as reported previously
[26]. The detection limit was 0.1 ng/ml and mean intra- and
inter-assay CVs were 7% and 10% respectively. Concentrations of
estradiol-17b in GC-conditioned media were determined by
radioimmunoassay [48]. The detection limit of the assay was
2 pg/ml and mean intra- and inter-assay CVs were 6% and 9%
respectively. Concentrations of progesterone in conditioned media
from both cell-types were determined by competitive ELISA [49].
The detection limit was 0.1 ng/ml and mean intra- and inter-assay
CVs were 8% and 11% respectively.
Purification of RNA, cDNA Synthesis and Real-time PCR
Total RNA was isolated from cultured cells using Tri-Reagent
(Sigma). Briefly, cell monolayers were lysed in Tri Reagent
(0.5 ml/well) and after aqueous phase separation, RNA was
precipitated in isopropanol, washed in 75% (v/v) ethanol and the
RNA pellet re-suspended in 50 ml nuclease-free water. Potential
genomic DNA contamination was removed with an RNase-free
DNase kit (RQ1; Promega UK Ltd, Southampton, UK). The Tri
Reagent extraction process was repeated and the final RNA pellet
re-suspended in 20 ml nuclease-free water; RNA quantity and
quality were evaluated by spectrophotometry at 260/280 nm.
First strand cDNA was synthesized from 1 mg of RNA template
using the Reverse-iT reverse transcription kit (used according to
manufacturers protocol; Abgene, Epsom, Surrey, UK) in a 20 ml
reaction primed with random hexamers.
Primers (see table 1) were designed to amplify target sequences
using Primer Express software (version 1.5, Applied Biosystems).
In primer validation experiments melt curve analysis and agarose
gel electrophoresis were used to verify that each primer pair
generated a single product of the predicted size. cDNA template
log-dilution curves were used to demonstrate satisfactory PCR
efficiency (.85%) and linearity. PCR assays were carried out in a
volume of 24 ml, comprising 10 ml cDNA template (equivalent to
20 ng reverse-transcribed RNA), 1ml each forward and reverse
primers (final concentration 0.4 mM) and 12 ml QuantiTect SYBR
Green QPCR 26 Master Mix (Qiagen, UK). Samples were
processed on an ABI PRISMH 7700 Sequence Detection System
(Perkin Elmer-Applied Biosystems, Warrington, UK) with the
following thermal cycling conditions: 2 min at 50uC, 15 min at
95uC (one cycle) followed by 15 s at 95uC and 1 min at 60uC (40
cycles).
The DDCt method [50] was used for comparison of the relative
abundance of each mRNA transcript in TC and GC. Ct values for
each transcript in a given sample were first normalized to b-actin
Ct value (which was uniform across experimental all groups:
ANOVA P.0.1). Resultant DCt values for individual replicates
within each treatment group were then normalized to the average
DCt value of the respective vehicle-treated control group. These
DDCt values were finally converted to fold-differences using the
formula: fold-difference = 2(2DDCt).
Statistical Analysis
Results for hormone secretion (during final 96–144 h period of
culture) and cell number at the end of culture were analysed using
two-way analysis of variance (ANOVA) and are presented as
means 6 SEM based on 4 independent culture experiments. To
reduce heterogeneity of variance, hormone data were log-
transformed prior to statistical analysis. QPCR data (from n= 7
independent TC batches, n = 4 independent GC batches) were
statistically analysed (ANOVA and post-hoc Fisher’s PLSD test) as
DCt values before conversion to fold-difference values for
graphical presentation.
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